Developer docs
API playgroundTry for free, no card

Search company profiles

SheMed

Full company profile

uuid003qd5c

Namestring
SheMed
Legal namestring
SheMed
Websiteurl
shemed.co.uk
Company typeenum
Private
Founded yearint
2024
Descriptiontext

SheMed is a London-based, female-founded women's health technology company operating a direct-to-consumer telehealth platform for clinician-led weight management. Founded in April 2024 by sisters Olivia and Chloe Ferro, the company serves UK women aged 18-85 who meet NHS-style eligibility for weight-loss medication (BMI ≥30, or ≥27 with comorbidities), with particular emphasis on cohorts under-served by mainstream providers — women navigating perimenopause, menopause, and PMOS/PCOS. The platform combines at-home needle-free blood testing (using Tasso device technology for HbA1c, cholesterol, liver, and kidney screening), clinician-led prescribing of Wegovy, Mounjaro, and oral semaglutide, and an all-in-one mobile app for ordering, progress tracking, weekly check-ins, and clinician messaging. Pharmacy dispensing and clinical/prescribing services are delivered through partner eMed Healthcare UK, a GPhC-registered pharmacy (#9012578) and CQC-registered provider (#1-1690359844), making regulatory compliance a partnership dependency rather than an in-house capability.

SheMed runs a subscription revenue model with monthly plans starting at £59 in the first promotional month (bundling a £100 blood test, medication, clinical support, and a side-effect care package), then from £139/month rolling, plus 3/6/12-month commitment tiers with early-termination fees, and two £24.99/month supplement add-ons (GLP-1 Daily Support & Sleep; Hair, Skin & Nails). Marketing is digital-first — content/SEO, email, paid social, a £40/head referral programme, an affiliate programme tracked via Rewardful, and a Birmingham City FC sponsorship — and the entire customer journey runs through a self-serve online eligibility quiz and the SheMed app. The company scaled to 100,000+ UK members within roughly 18 months, raising a $50 million Series A in October 2025 at a $1 billion valuation (unicorn status) and setting an explicit target of 250,000 women by 2026.

The clinical differentiator is a female-specific protocol layer addressing hormonal drivers of weight gain that mainstream GLP-1 programmes ignore, supported by a 12-month real-world evidence study launched in December 2024 (results expected early 2026) examining outcomes beyond weight loss in PMOS, endometriosis, menopause, and cardiometabolic health. The Wegovy oral pill, launched in 2026 as a needle-free alternative, further broadens the addressable market. Geographic concentration is currently total — UK only — and operational scale remains a single-market bet, with all clinical, pharmacy, and distribution infrastructure routed through one regulated pharmacy partner.

Short descriptiontext

SheMed is a London-based, female-founded telehealth platform offering clinician-led GLP-1 weight-management programmes tailored for UK women, combining at-home needle-free blood testing, personalised prescribing, and app-based monitoring for 100,000+ members.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
women's health technology, medical weight loss, GLP-1 medication programmes, at-home blood testing, telehealth weight management
Industry2 codes
PRIMARYHLALAAAD
Prescription-Based Digital Clinics (Condition-Specific Rx Programs)
Healthcare & Life Sciences/Telehealth Platforms/Direct-to-Consumer Virtual Care Platforms
SECONDARYHLALAIAH
Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
NAICS code1 code
  • Other Ambulatory Health Care Services6219
SIC code1 code
  • Services-Health Services8000
Product category
Women's Telehealth Weight Management
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Weight Loss Programme Subscription
TypeSubscription Recurring
Description

Monthly subscription plans (rolling monthly, 3-month, 6-month, 12-month) bundling blood tests, GLP-1 medication (Wegovy/Mounjaro), clinical support, app access, and side-effect care. First month from £59, then from £139/month.

shemed.co.uk
2Supplements
TypeSubscription Recurring
Description

GPL-1 Daily Support & Sleep (£24.99/month) and Hair, Skin & Nails (£24.99/month) supplements sold as add-on subscriptions to programme members.

shemed.co.uk
3Affiliate Commission
TypeAffiliate Referral
Description

UK-based affiliates earn commission for each successful referral who completes their first order. Paid monthly via PayPal.

shemed.co.uk
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Pricing details6 tiers
1First month promotional price
ModelSubscriptionBilling cadenceMonthly
Notes

First month from £59 including blood test worth £100, medication, and clinical support.

shemed.co.uk
2Rolling monthly subscription
ModelSubscriptionBilling cadenceMonthly
Notes

From £139/month after first month. Includes everything: blood tests, medication, clinical support, app access, side-effect care. Cancel anytime with 21 days notice.

shemed.co.uk
33/6/12-month commitment plans
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Longer commitment plans offer best savings compared to rolling monthly. Early termination fee may apply.

shemed.co.uk
4GPL-1 Daily Support & Sleep supplement
ModelSubscriptionBilling cadenceMonthly
Notes

£24.99 per month. 28-day supply (56 capsules). Rolling subscription, cancel anytime. Includes magnesium glycinate for GLP-1 users.

shemed.co.uk
5Hair, Skin & Nails supplement
ModelSubscriptionBilling cadenceMonthly
Notes

£24.99 per month. 28-day supply (56 capsules). Rolling subscription, cancel anytime. Hydrolysed marine collagen with vitamin C and biotin.

shemed.co.uk
6Wegovy pill (oral semaglutide)
ModelSubscriptionBilling cadenceMonthly
Notes

Wegovy pill starts from £69/month, including clinical support, blood test, and side effects care. Available privately; NHS access unlikely before 2027.

shemed.co.uk
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

SheMed is a UK women's health technology company offering a clinician-led, personalised medical weight loss programme built around GLP-1 medications (Wegovy and Mounjaro injections, plus oral Wegovy pill). The service combines at-home needle-free blood testing for metabolic screening, ongoing clinician oversight, and an all-in-one mobile app for ordering, tracking, and check-ins. Membership is delivered via recurring subscription bundles that include medication, blood tests, clinical support, and side-effect care.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Members can lose up to 28% of body weight
+5 more records
Product overview1 text field

SheMed is a UK-based women's health technology company offering a personalised, clinician-led medical weight loss programme built around GLP-1 medications. The core offering is the SheMed Medical Weight Loss Programme, which combines Wegovy (semaglutide) and Mounjaro (tirzepatide) in both injectable and oral (Wegovy pill) forms, supported by at-home needle-free blood testing and metabolic monitoring. Members access care through a companion mobile app providing progress tracking, weekly check-ins, and clinician support. Supplementary offerings include two branded supplements (GLP-1 Daily Support & Sleep, and Hair, Skin & Nails), an ongoing clinical study investigating women's health outcomes beyond weight loss, a referral programme (£40 per successful referral), and an affiliate programme for UK-based promoters tracked via Rewardful. The pharmacy and prescribing services are delivered in partnership with eMed Healthcare UK (GPhC- and CQC-registered).

Product and service5 records
1SheMed Medical Weight Loss Programme
CategoryWomen's telehealth weight loss programme
Description

Clinician-led, personalised medical weight loss programme for UK women using GLP-1 medications (Wegovy and Mounjaro injections or oral Wegovy pill), supported by at-home blood testing, metabolic monitoring, and an all-in-one mobile app for ordering, tracking, and clinician check-ins. Delivered as a monthly or multi-month subscription.

2Wegovy Pill (Oral Semaglutide)
CategoryOral GLP-1 weight loss medication
Description

MHRA-approved daily oral weight-loss tablet containing semaglutide, offered as a needle-free alternative to injectable GLP-1 therapy. Available privately from SheMed from £69/month including clinical support, blood test, and side-effect care.

3GLP-1 Injection Programme (Wegovy and Mounjaro)
CategoryInjectable GLP-1 weight loss medication
Description

Weekly injectable GLP-1 medications (Wegovy and Mounjaro) prescribed as part of a personalised weight-loss plan, including dose titration, metabolic monitoring, and the ability to switch between medications or delivery methods.

4At-Home Needle-Free Blood Test
CategoryAt-home diagnostic blood test
Description

Needle-free at-home blood screening using Tasso technology, included in SheMed programme plans. Tests for HbA1c, cholesterol, liver health, and kidney function at baseline, 6 months, and 12 months to support eligibility assessment and ongoing metabolic monitoring.

5SheMed Supplements
CategoryWellness supplements
Description

Two third-party-tested supplement products available exclusively to SheMed members as rolling monthly subscriptions (£24.99/month per product): GLP-1 Daily Support & Sleep (magnesium glycinate) and Hair, Skin & Nails (hydrolysed marine collagen with vitamin C and biotin), each supplied as a 28-day pack of 56 capsules.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1eMed Healthcare UK
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

GPhC-registered pharmacy partner (registration number 9012578, Superintendent Pharmacist Yee Lai, registration 2207949) providing dispensing and medication fulfilment. Clinical, consultation, and prescribing services provided by eMed (CQC-registered provider, registration 1-1690359844). All eMed clinicians are UK-registered and licensed.

shemed.co.uk
Strategic tierMinorTypeGTM or Marketing Partner
Description

SheMed is a proud sponsor of Birmingham City FC. Partnership includes promotional prize draws (game ticket raffles, Christmas Giveaway, seasonal promotions) and community health initiatives.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based digital weight management programme combining lifestyle coaching with optional GLP-1 medication prescribing. Comparable subscription model and UK focus, though with a stronger non-clinical coaching orientation.

2Juniper
TypeDirect peer
Description

UK-based telehealth subscription service providing clinician-led weight loss treatment with GLP-1 medications (Wegovy/Mounjaro) targeted at women. Directly comparable on geography, business model, and target demographic.

3Ro
TypeBroad incumbent
Description

US D2C telehealth platform with a dedicated weight loss programme (Ro Body) using GLP-1 medications, plus broader primary care and pharmacy. Comparable end-to-end digital clinic model, though US-focused and broader portfolio.

TypeDirect peer
Description

UK weight-loss telehealth subscription providing personalised plans with clinician support, GLP-1 medications, and app-based tracking. Direct UK competitor in the same female-inclusive D2C GLP-1 subscription category.

TypeDirect peer
Description

UK/European online doctor and pharmacy offering weight loss treatment, sexual health, and chronic condition management via online consultation and home delivery. Comparable D2C online-clinic model serving UK consumers with subscription prescriptions.

TypeBroad incumbent
Description

UK D2C men's health platform that has expanded into weight loss (including GLP-1 treatments). Comparable D2C subscription telehealth model targeting UK consumers, though historically men's health-focused.

7Babylon Health
TypeBroad incumbent
Description

Former UK digital primary care leader (now part of eMed) and prior employer of two SheMed C-suite executives. Provides the broader digital-health platform and clinical infrastructure underpinning UK telehealth, including the eMed pharmacy/prescribing partnership SheMed relies on.

TypeDirect peer
Description

UK digital health platform offering subscription-based access to clinician-prescribed treatments including weight loss (GLP-1s), men's health, and hair loss. Comparable on D2C telehealth subscription model and UK geographic focus.

TypeDirect peer
Description

UK digital weight loss programme offering clinician-led care with GLP-1 prescribing and behavioural support. Direct competitor on subscription-based remote weight management in the UK market.

TypeBroad incumbent
Description

US-listed D2C telehealth platform offering weight loss (GLP-1) subscriptions alongside broader wellness categories. Comparable subscription model and category mix, though US-focused and much larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SheMed

Women's Telehealth Weight Managementshemed.co.uk

SheMed is a London-based, female-founded telehealth platform offering clinician-led GLP-1 weight-management programmes tailored for UK women, combining at-home needle-free blood testing, personalised prescribing, and app-based monitoring for 100,000+ members.

What SheMed does

SheMed is a London-based, female-founded women's health technology company operating a direct-to-consumer telehealth platform for clinician-led weight management. Founded in April 2024 by sisters Olivia and Chloe Ferro, the company serves UK women aged 18-85 who meet NHS-style eligibility for weight-loss medication (BMI ≥30, or ≥27 with comorbidities), with particular emphasis on cohorts under-served by mainstream providers — women navigating perimenopause, menopause, and PMOS/PCOS. The platform combines at-home needle-free blood testing (using Tasso device technology for HbA1c, cholesterol, liver, and kidney screening), clinician-led prescribing of Wegovy, Mounjaro, and oral semaglutide, and an all-in-one mobile app for ordering, progress tracking, weekly check-ins, and clinician messaging. Pharmacy dispensing and clinical/prescribing services are delivered through partner eMed Healthcare UK, a GPhC-registered pharmacy (#9012578) and CQC-registered provider (#1-1690359844), making regulatory compliance a partnership dependency rather than an in-house capability.

SheMed runs a subscription revenue model with monthly plans starting at £59 in the first promotional month (bundling a £100 blood test, medication, clinical support, and a side-effect care package), then from £139/month rolling, plus 3/6/12-month commitment tiers with early-termination fees, and two £24.99/month supplement add-ons (GLP-1 Daily Support & Sleep; Hair, Skin & Nails). Marketing is digital-first — content/SEO, email, paid social, a £40/head referral programme, an affiliate programme tracked via Rewardful, and a Birmingham City FC sponsorship — and the entire customer journey runs through a self-serve online eligibility quiz and the SheMed app. The company scaled to 100,000+ UK members within roughly 18 months, raising a $50 million Series A in October 2025 at a $1 billion valuation (unicorn status) and setting an explicit target of 250,000 women by 2026.

The clinical differentiator is a female-specific protocol layer addressing hormonal drivers of weight gain that mainstream GLP-1 programmes ignore, supported by a 12-month real-world evidence study launched in December 2024 (results expected early 2026) examining outcomes beyond weight loss in PMOS, endometriosis, menopause, and cardiometabolic health. The Wegovy oral pill, launched in 2026 as a needle-free alternative, further broadens the addressable market. Geographic concentration is currently total — UK only — and operational scale remains a single-market bet, with all clinical, pharmacy, and distribution infrastructure routed through one regulated pharmacy partner.

SheMed firmographics

Firmographics
Name
SheMed
Legal name
SheMed
Website
https://shemed.co.uk
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
SheMed is a London-based, female-founded telehealth platform offering clinician-led GLP-1 weight-management programmes tailored for UK women, combining at-home needle-free blood testing, personalised prescribing, and app-based monitoring for 100,000+ members.
Ownership category
akta.pro rank

SheMed industry classification

Industry
Product category
Women's Telehealth Weight Management
NAICS
Other Ambulatory Health Care Services (6219)
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLALAAAD
Prescription-Based Digital Clinics (Condition-Specific Rx Programs)
Healthcare & Life Sciences/Telehealth Platforms/Direct-to-Consumer Virtual Care Platforms
SECONDARYHLALAIAH
Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms

Keywords

  • Women's health technology
  • Medical weight loss
  • GLP-1 medication programmes
  • At-home blood testing
  • Telehealth weight management

Where SheMed is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

SheMed business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. Weight Loss Programme Subscription: Monthly subscription plans (rolling monthly, 3-month, 6-month, 12-month) bundling blood tests, GLP-1 medication (Wegovy/Mounjaro), clinical support, app access, and side-effect care. First month from £59, then from £139/month.
  2. Supplements: GPL-1 Daily Support & Sleep (£24.99/month) and Hair, Skin & Nails (£24.99/month) supplements sold as add-on subscriptions to programme members.
  3. Affiliate Commission: UK-based affiliates earn commission for each successful referral who completes their first order. Paid monthly via PayPal.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyFirst month promotional price
SubscriptionMonthlyRolling monthly subscription
SubscriptionMulti-year contract3/6/12-month commitment plans
SubscriptionMonthlyGPL-1 Daily Support & Sleep supplement
SubscriptionMonthlyHair, Skin & Nails supplement
SubscriptionMonthlyWegovy pill (oral semaglutide)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

SheMed product offering

Product offering

Core offering

SheMed is a UK women's health technology company offering a clinician-led, personalised medical weight loss programme built around GLP-1 medications (Wegovy and Mounjaro injections, plus oral Wegovy pill). The service combines at-home needle-free blood testing for metabolic screening, ongoing clinician oversight, and an all-in-one mobile app for ordering, tracking, and check-ins. Membership is delivered via recurring subscription bundles that include medication, blood tests, clinical support, and side-effect care.

Product overview

SheMed is a UK-based women's health technology company offering a personalised, clinician-led medical weight loss programme built around GLP-1 medications. The core offering is the SheMed Medical Weight Loss Programme, which combines Wegovy (semaglutide) and Mounjaro (tirzepatide) in both injectable and oral (Wegovy pill) forms, supported by at-home needle-free blood testing and metabolic monitoring. Members access care through a companion mobile app providing progress tracking, weekly check-ins, and clinician support. Supplementary offerings include two branded supplements (GLP-1 Daily Support & Sleep, and Hair, Skin & Nails), an ongoing clinical study investigating women's health outcomes beyond weight loss, a referral programme (£40 per successful referral), and an affiliate programme for UK-based promoters tracked via Rewardful. The pharmacy and prescribing services are delivered in partnership with eMed Healthcare UK (GPhC- and CQC-registered).

Differentiator

Problem solved

Functional benefit

Products and services

  • SheMed Medical Weight Loss Programme Clinician-led, personalised medical weight loss programme for UK women using GLP-1 medications (Wegovy and Mounjaro injections or oral Wegovy pill), supported by at-home blood testing, metabolic monitoring, and an all-in-one mobile app for ordering, tracking, and clinician check-ins. Delivered as a monthly or multi-month subscription.
  • Wegovy Pill (Oral Semaglutide) MHRA-approved daily oral weight-loss tablet containing semaglutide, offered as a needle-free alternative to injectable GLP-1 therapy. Available privately from SheMed from £69/month including clinical support, blood test, and side-effect care.
  • GLP-1 Injection Programme (Wegovy and Mounjaro) Weekly injectable GLP-1 medications (Wegovy and Mounjaro) prescribed as part of a personalised weight-loss plan, including dose titration, metabolic monitoring, and the ability to switch between medications or delivery methods.
  • At-Home Needle-Free Blood Test Needle-free at-home blood screening using Tasso technology, included in SheMed programme plans. Tests for HbA1c, cholesterol, liver health, and kidney function at baseline, 6 months, and 12 months to support eligibility assessment and ongoing metabolic monitoring.
  • SheMed Supplements Two third-party-tested supplement products available exclusively to SheMed members as rolling monthly subscriptions (£24.99/month per product): GLP-1 Daily Support & Sleep (magnesium glycinate) and Hair, Skin & Nails (hydrolysed marine collagen with vitamin C and biotin), each supplied as a 28-day pack of 56 capsules.

Quantifiable outcome

  • Members can lose up to 28% of body weight
  • +5 more outcomes

Companies that use SheMed

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

SheMed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

SheMed partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • eMed Healthcare UKcoreImplementation/ SI/ Consulting PartnerGPhC-registered pharmacy partner (registration number 9012578, Superintendent Pharmacist Yee Lai, registration 2207949) providing dispensing and medication fulfilment. Clinical, consultation, and prescribing services provided by eMed (CQC-registered provider, registration 1-1690359844). All eMed clinicians are UK-registered and licensed.
  • Birmingham City Football ClubminorGTM or Marketing PartnerSheMed is a proud sponsor of Birmingham City FC. Partnership includes promotional prize draws (game ticket raffles, Christmas Giveaway, seasonal promotions) and community health initiatives.

Scale indicators7 records

Recent moves5 records

Expansion highlights6 records

SheMed competitors and assessment

Company assessment

Direct peers

  • Second Nature: UK-based digital weight management programme combining lifestyle coaching with optional GLP-1 medication prescribing. Comparable subscription model and UK focus, though with a stronger non-clinical coaching orientation.
  • Juniper: UK-based telehealth subscription service providing clinician-led weight loss treatment with GLP-1 medications (Wegovy/Mounjaro) targeted at women. Directly comparable on geography, business model, and target demographic.
  • Voy: UK weight-loss telehealth subscription providing personalised plans with clinician support, GLP-1 medications, and app-based tracking. Direct UK competitor in the same female-inclusive D2C GLP-1 subscription category.
  • Zava: UK/European online doctor and pharmacy offering weight loss treatment, sexual health, and chronic condition management via online consultation and home delivery. Comparable D2C online-clinic model serving UK consumers with subscription prescriptions.
  • Numan: UK digital health platform offering subscription-based access to clinician-prescribed treatments including weight loss (GLP-1s), men's health, and hair loss. Comparable on D2C telehealth subscription model and UK geographic focus.
  • Habitual: UK digital weight loss programme offering clinician-led care with GLP-1 prescribing and behavioural support. Direct competitor on subscription-based remote weight management in the UK market.

Broad incumbents

  • Ro: US D2C telehealth platform with a dedicated weight loss programme (Ro Body) using GLP-1 medications, plus broader primary care and pharmacy. Comparable end-to-end digital clinic model, though US-focused and broader portfolio.
  • Manual: UK D2C men's health platform that has expanded into weight loss (including GLP-1 treatments). Comparable D2C subscription telehealth model targeting UK consumers, though historically men's health-focused.
  • Babylon Health: Former UK digital primary care leader (now part of eMed) and prior employer of two SheMed C-suite executives. Provides the broader digital-health platform and clinical infrastructure underpinning UK telehealth, including the eMed pharmacy/prescribing partnership SheMed relies on.
  • Hims & Hers Health: US-listed D2C telehealth platform offering weight loss (GLP-1) subscriptions alongside broader wellness categories. Comparable subscription model and category mix, though US-focused and much larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

SheMed social profiles

Digital presence

SheMed compliance and trust

Trust signal

Compliance2 records

SheMed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SheMed leadership team

Management profile

Number of profiles

Profiles9 records

SheMed funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SheMed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SheMed

What does SheMed do?

SheMed is a UK women's health technology company offering a clinician-led, personalised medical weight loss programme built around GLP-1 medications (Wegovy and Mounjaro injections, plus oral Wegovy pill). The service combines at-home needle-free blood testing for metabolic screening, ongoing clinician oversight, and an all-in-one mobile app for ordering, tracking, and check-ins. Membership is delivered via recurring subscription bundles that include medication, blood tests, clinical support, and side-effect care.

Is SheMed a public or private company?

SheMed is a private company. It is classified as venture growth investor backed and is currently operating.

When was SheMed founded?

SheMed was founded in 2024. It employs 11 to 50 people.

Where is SheMed based?

SheMed is headquartered in London, United Kingdom, in the Europe region.

How does SheMed make money?

Three revenue lines are on record. Weight Loss Programme Subscription is the primary driver. The others are supplements and affiliate Commission.

Who are SheMed's main competitors?

Direct peers on record are Second Nature, Juniper, Voy, Zava, Numan and Habitual. Broad incumbents are Ro, Manual, Babylon Health and Hims & Hers Health.

Does SheMed have an API?

No public API is recorded for SheMed.

What industry is SheMed in?

SheMed's product category is Women's Telehealth Weight Management. Its primary akta.pro industry code is HLALAAAD, Prescription-Based Digital Clinics (Condition-Specific Rx Programs), with a secondary code of HLALAIAH, Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing. Its NAICS code is 6219 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Inc.SheMed Built a $1 Billion Business on GLP-1s. Its Next Bet Goes Beyond Weight LossSheMed, a London-based telehealth company, published a study of over 8,000 women on GLP-1 tirzepatide, finding average weight loss of 15.5% and improved blood sugar and cholesterol. The company raised $50 million in a Series A round, valuing it at $1 billion.PR NewswireNature Medicine Study of 8,000+ Women Finds Significant Weight Loss and 91% Treatment Retention With Digital GLP-1 CareA Nature Medicine study of 8,127 women found that GLP-1 treatment via SheMed's digital care program yielded an average 15.5% weight loss and 91.4% retention at six months. Metabolic health improved, with 84.5% of those with diabetes-range glucose returning to normal HbA1c. The findings highlight real-world performance of GLP-1 therapy outside clinical trials.ForbesUnicorn Healthcare Startup SheMed Expands Beyond GLP-1s To Women’s At-Home Health ScreeningsSheMed, a UK-based healthcare startup, expanded from GLP-1 medications to at-home blood testing for polyendocrine metabolic ovarian syndrome (PMOS). The new PMOS kits cost £149 and test 19 metrics, with results delivered within a week. The company plans to expand beyond the UK within the next year.Med-Tech InsightsWomen’s health draws record in equityWomen's health companies raised a record $1.55 billion in disclosed equity in 2025, up 39% year on year. The top three rounds' share fell from 39% to 32%, while funding to outside companies grew 56%. A Series A bottleneck remains, with only 20-25 companies reaching that stage annually.Medical Device NetworkWomen’s health attracted record equity in 2025 as companies share capitalWomen's health companies secured a record $1.55bn in equity funding in 2025, up 41% from 2024, with 85 companies raising capital—the highest single-year count ever recorded, according to a report from W Group. The report highlights that funding is diversifying beyond top rounds, with the share of capital held by the three largest rounds falling from 39% to 32%, while funding to companies outside the top three grew 56% year-on-year. Notable raises included ReproNovo's $65m Series A, SheMed's $50m Series A, Midi Health's $50m Series C, and Gameto's $44m Series C, with the Bill & Melinda Gates Foundation also pledging $2.5bn through 2030 for women's health R&D.PR NewswireSheMed Launches Oral Wegovy in the UKSheMed will begin offering oral Wegovy on July 7, giving eligible patients a needle-free alternative to injectable GLP-1 medications. The company priced the first month at £69, with monthly costs from £154 to £269 depending on dosage. Clinical data from Novo Nordisk's OASIS programme showed average weight loss of about 16.6% over 64 weeks.AthletechnewsGLP-1 Use Doubles Across America — Here’s Who’s Taking ThemAccording to the Gallup National Health and Well-Being Index, 12.4% of U.S. adults are now using GLP-1 drugs like Ozempic and Wegovy for weight loss, more than doubling from 5.8% in early 2024, with nearly 90% of Americans now aware of the drugs. Women lead adoption at 15.2% compared to 9.7% for men, while adults aged 50 to 64 show the highest usage rates at 17%, with adoption notably lower among younger adults and those 65 and older. Multiple health startups and telehealth platforms, including SheMed, Andel, Midi Health, and Noom, have recently raised funding or launched celebrity partnerships to expand GLP-1-powered weight management and menopause services.FemTech WorldSheMed raises €43m to scale UK operationsSheMed has raised €43 million to expand its operations in the UK, focusing on femtech products that are regulated as medical devices or consumer products. The article discusses regulatory frameworks, market trends, and technological advancements influencing femtech, IVF, and reproductive health device development. It emphasizes the importance of compliance, cost management, and digital integration for manufacturers aiming to succeed in the evolving fertility market.ReutersWomen-focused weight-loss startup SheMed raises $50 million at $1 billion valuationLondon-based telehealth startup SheMed raised $50 million in a Series A round on October 23, valuing the company at $1 billion, as demand for weight-loss drugs Wegovy and Mounjaro grows in Britain. Founded in April 2024 by sisters Olivia and Chloe Ferro, SheMed has signed up more than 60,000 members in under a year, offering personalized weight-loss programs for women that pair GLP-1 medication with health screenings and ongoing support. The company plans to use the funding to expand across the United Kingdom, back research initiatives, and publish a study on how GLP-1 medicines affect hormonal and metabolic health.PR NewswireSheMed Achieves Unicorn Status with $50M Raise to Scale Personalised Women's HealthcareSheMed, a female-founded UK health technology company, announced it has raised $50 million at a $1 billion valuation, achieving unicorn status to scale its personalised women's healthcare platform. Founded in 2024 by sisters Olivia and Chloe Ferro, the company has grown to over 60,000 members in under a year, becoming the fastest growing GLP-1 weight-management programme in the UK. The funding will be used to expand medical and technology teams, strengthen clinical infrastructure, and support new research including the publication of the first-ever female-focused GLP-1 clinical study later this month.